Pulse-Controlled Amplification Tested for Infectious Disease Diagnostics
By LabMedica International staff writers Posted on 25 Feb 2021 |

Image: The Pharos Micro prototype used in pulse-controlled amplification for infectious disease diagnostics (Photo courtesy of Bundeswehr Institute of Microbiology).
Molecular diagnostics has become essential in the identification of many infectious and neglected diseases, and the detection of nucleic acids often serves as the gold standard technique for most infectious agents.
However, established techniques like polymerase chain reaction (PCR) are time-consuming laboratory-bound techniques while rapid tests such as Lateral Flow Immunochromatographic tests often lack the required sensitivity and/or specificity.
A team of medical microbiologists led by the Bundeswehr Institute of Microbiology (Munich, Germany) scientists developed an affordable, highly mobile alternative method for the rapid identification of infectious agents using pulse-controlled amplification (PCA). PCA is a next generation nucleic acid amplification technology that uses rapid energy pulses to heat microcyclers (micro-scale metal heating elements embedded directly in the amplification reaction) for a few microseconds, thus only heating a small fraction of the reaction volume. The heated microcyclers cool off nearly instantaneously, resulting in ultra-fast heating and cooling cycles during which classic amplification of a target sequence takes place. This reduces the overall amplification time by a factor of up to 10, enabling a sample-to-result workflow in just 15 minutes, while running on a small and portable prototype device.
The team used the Pharos Micro prototype (GNA Biosolutions, Martinsried, Germany) that consists of a 3D-printed housing and lid with a size of 100mm × 175 mm × 110 mm (W×D×H) and weighs 900 grams. The instrument is equipped with light-emitting diodes and filters for real-time fluorescence detection and electronic control modules. Two conventional heating blocks are set to a constant temperature at the bottom and the top of the chip to maintain the reaction volume at a constant temperature of 65 °C for annealing and elongation. The Pharos Micro prototype is battery-powered for field use (using a commercially available power bank) or can be connected to a power supply (230 V) in the stationary laboratory.
In this proof of principle study, the scientists designed a PCA-assay for the detection of Yersinia pestis to demonstrate the efficacy of this technology. The observed detection limits were 434 copies per reaction (purified DNA) and 35 cells per reaction (crude sample) respectively of Y. pestis. The team used the miPROTECT Plague (Miprolab, Göttingen, Germany) lateral flow assay as the standard reference method for the detection of Y. pestis in liquid culture under field conditions. Tests were performed and results were obtained after 20 minutes.
The authors concluded they had demonstrated a novel ultra-fast method for the amplification and detection of nucleic acid through Pulse Controlled Amplification (PCA). PCA combines the speed of LFAs or isothermal methods, with the simplicity of assay design of PCR, in a novel portable and battery operated system. The work successfully demonstrated example applications for PCA in the detection of Y. pestis, under laboratory, point-of-care and field conditions. It expands the use of molecular testing to extra-laboratory or non-traditional laboratory settings, as well as near-patient setting, and has the potential to become a powerful technology in nucleic acid detection for front-line and in-field applications. The study was published on January 29, 2021 in the journal PLOS Neglected Tropical Diseases.
Related Links:
Bundeswehr Institute of Microbiology
GNA Biosolutions
Miprolab
However, established techniques like polymerase chain reaction (PCR) are time-consuming laboratory-bound techniques while rapid tests such as Lateral Flow Immunochromatographic tests often lack the required sensitivity and/or specificity.
A team of medical microbiologists led by the Bundeswehr Institute of Microbiology (Munich, Germany) scientists developed an affordable, highly mobile alternative method for the rapid identification of infectious agents using pulse-controlled amplification (PCA). PCA is a next generation nucleic acid amplification technology that uses rapid energy pulses to heat microcyclers (micro-scale metal heating elements embedded directly in the amplification reaction) for a few microseconds, thus only heating a small fraction of the reaction volume. The heated microcyclers cool off nearly instantaneously, resulting in ultra-fast heating and cooling cycles during which classic amplification of a target sequence takes place. This reduces the overall amplification time by a factor of up to 10, enabling a sample-to-result workflow in just 15 minutes, while running on a small and portable prototype device.
The team used the Pharos Micro prototype (GNA Biosolutions, Martinsried, Germany) that consists of a 3D-printed housing and lid with a size of 100mm × 175 mm × 110 mm (W×D×H) and weighs 900 grams. The instrument is equipped with light-emitting diodes and filters for real-time fluorescence detection and electronic control modules. Two conventional heating blocks are set to a constant temperature at the bottom and the top of the chip to maintain the reaction volume at a constant temperature of 65 °C for annealing and elongation. The Pharos Micro prototype is battery-powered for field use (using a commercially available power bank) or can be connected to a power supply (230 V) in the stationary laboratory.
In this proof of principle study, the scientists designed a PCA-assay for the detection of Yersinia pestis to demonstrate the efficacy of this technology. The observed detection limits were 434 copies per reaction (purified DNA) and 35 cells per reaction (crude sample) respectively of Y. pestis. The team used the miPROTECT Plague (Miprolab, Göttingen, Germany) lateral flow assay as the standard reference method for the detection of Y. pestis in liquid culture under field conditions. Tests were performed and results were obtained after 20 minutes.
The authors concluded they had demonstrated a novel ultra-fast method for the amplification and detection of nucleic acid through Pulse Controlled Amplification (PCA). PCA combines the speed of LFAs or isothermal methods, with the simplicity of assay design of PCR, in a novel portable and battery operated system. The work successfully demonstrated example applications for PCA in the detection of Y. pestis, under laboratory, point-of-care and field conditions. It expands the use of molecular testing to extra-laboratory or non-traditional laboratory settings, as well as near-patient setting, and has the potential to become a powerful technology in nucleic acid detection for front-line and in-field applications. The study was published on January 29, 2021 in the journal PLOS Neglected Tropical Diseases.
Related Links:
Bundeswehr Institute of Microbiology
GNA Biosolutions
Miprolab
Latest Microbiology News
- Molecular Stool Test Shows Potential for Diagnosing TB in Adults with HIV
- New Test Diagnoses Bacterial Meningitis Quickly and Accurately
- Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
- New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
- Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
- Innovative ID/AST System to Help Diagnose Infectious Diseases and Combat AMR
- Gastrointestinal Panel Delivers Rapid Detection of Five Common Bacterial Pathogens for Outpatient Use
- Rapid PCR Testing in ICU Improves Antibiotic Stewardship
- Unique Genetic Signature Predicts Drug Resistance in Bacteria
- Unique Barcoding System Tracks Pneumonia-Causing Bacteria as They Infect Blood Stream
- Rapid Sepsis Diagnostic Test Demonstrates Improved Patient Care and Cost Savings in Hospital Application
- Rapid Diagnostic System to Detect Neonatal Sepsis Within Hours
- Novel Test to Diagnose Bacterial Pneumonia Directly from Whole Blood
- Interferon-γ Release Assay Effective in Patients with COPD Complicated with Pulmonary Tuberculosis
- New Point of Care Tests to Help Reduce Overuse of Antibiotics
- 30-Minute Sepsis Test Differentiates Bacterial Infections, Viral Infections, and Noninfectious Disease
Channels
Clinical Chemistry
view channelMass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication
Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more
First Comprehensive Syphilis Test to Definitively Diagnose Active Infection In 10 Minutes
In the United States, syphilis cases have surged by nearly 80% from 2018 to 2023, with 209,253 cases recorded in the most recent year of data. Syphilis, which can be transmitted sexually or from mother... Read more
Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse
Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read moreMolecular Diagnostics
view channel
First-in-Class Diagnostic Blood Test Detects Axial Spondyloarthritis
Axial spondyloarthritis (axSpA) is a chronic inflammatory autoimmune condition that typically affects individuals during their most productive years, with symptoms often emerging before the age of 45.... Read more
New Molecular Label to Help Develop Simpler and Faster Tuberculosis Tests
Tuberculosis (TB), the deadliest infectious disease globally, is responsible for infecting an estimated 10 million people each year and causing over 1 million deaths annually. While chest X-rays and molecular... Read more
Biomarker Discovery Paves Way for Blood Tests to Detect and Treat Osteoarthritis
The number of individuals affected by osteoarthritis is projected to exceed 1 billion by 2050. The primary risk factor for this common, often painful chronic joint condition is aging, and, like aging itself,... Read moreHematology
view channel
First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes
Heparin dosing requires careful management to avoid both bleeding and clotting complications. In high-risk situations like extracorporeal membrane oxygenation (ECMO), mortality rates can reach about 50%,... Read more
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read morePathology
view channel
Groundbreaking Chest Pain Triage Algorithm to Transform Cardiac Care
Cardiovascular disease is responsible for a third of all deaths worldwide, and chest pain is the second most common reason for emergency department (ED) visits. With EDs often being some of the busiest... Read more
AI-Based Liquid Biopsy Approach to Revolutionize Brain Cancer Detection
Detecting brain cancers remains extremely challenging, with many patients only receiving a diagnosis at later stages after symptoms like headaches, seizures, or cognitive issues appear. Late-stage diagnoses... Read moreTechnology
view channel
Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer
Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses
Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more